Search

Your search keyword '"Mitra, Siddhartha S."' showing total 171 results
Start Over Author "Mitra, Siddhartha S." Publication Year Range Last 50 years
171 results on '"Mitra, Siddhartha S."'

1. Publisher Correction: Notch1 regulates the initiation of metastasis and self-renewal of Group 3 medulloblastoma.

Author

Kahn, Suzana A, Wang, Xin, Nitta, Ryan T, Gholamin, Sharareh, Theruvath, Johanna, Hutter, Gregor, Azad, Tej D, Wadi, Lina, Bolin, Sara, Ramaswamy, Vijay, Esparza, Rogelio, Liu, Kun-Wei, Edwards, Michael, Swartling, Fredrik J, Sahoo, Debashis, Li, Gordon, Wechsler-Reya, Robert J, Reimand, Jüri, Cho, Yoon-Jae, Taylor, Michael D, Weissman, Irving L, Mitra, Siddhartha S, and Cheshier, Samuel H

Abstract

The original version of this Article omitted Suzana A. Kahn, Siddhartha S. Mitra & Samuel H. Cheshier as jointly supervising authors. This has now been corrected in both the PDF and HTML versions of the Article.

Published
2018

3. Unraveling the complexity of the senescence-associated secretory phenotype in adamantinomatous craniopharyngioma using multimodal machine learning analysis

Author

Prince, Eric W, primary, Apps, John R, additional, Jeang, John, additional, Chee, Keanu, additional, Medlin, Stephen, additional, Jackson, Eric M, additional, Dudley, Roy, additional, Limbrick, David, additional, Naftel, Robert, additional, Johnston, James, additional, Feldstein, Neil, additional, Prolo, Laura M, additional, Ginn, Kevin, additional, Niazi, Toba, additional, Smith, Amy, additional, Kilburn, Lindsay, additional, Chern, Joshua, additional, Leonard, Jeffrey, additional, Lam, Sandi, additional, Hersh, David S, additional, Gonzalez-Meljem, Jose Mario, additional, Amani, Vladimir, additional, Donson, Andrew M, additional, Mitra, Siddhartha S, additional, Bandopadhayay, Pratiti, additional, Martinez-Barbera, Juan Pedro, additional, and Hankinson, Todd C, additional

Published
2024
Full Text
View/download PDF

4. Microglia in the Brain Tumor Microenvironment

Author

Cole, Allison P., Hoffmeyer, Eric, Chetty, Senthilnath Lakshmana, Cruz-Cruz, Joselyn, Hamrick, Forrest, Youssef, Osama, Cheshier, Samuel, Mitra, Siddhartha S., Crusio, Wim E., Series Editor, Dong, Haidong, Series Editor, Radeke, Heinfried H., Series Editor, Rezaei, Nima, Series Editor, Xiao, Junjie, Series Editor, and Birbrair, Alexander, editor

Published
2020
Full Text
View/download PDF

6. Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid/rhabdoid tumors

Author

Theruvath, Johanna, Sotillo, Elena, Mount, Christopher W., Graef, Claus Moritz, Delaidelli, Alberto, Heitzeneder, Sabine, Labanieh, Louai, Dhingra, Shaurya, Leruste, Amaury, Majzner, Robbie G., Xu, Peng, Mueller, Sabine, Yecies, Derek W., Finetti, Martina A., Williamson, Daniel, Johann, Pascal D., Kool, Marcel, Pfister, Stefan, Hasselblatt, Martin, Fruhwald, Michael C., Delattre, Olivier, Surdez, Didier, Bourdeaut, Franck, Puget, Stephanie, Zaidi, Sakina, Mitra, Siddhartha S., Cheshier, Samuel, Sorensen, Poul H., Monje, Michelle, and Mackall, Crystal L.

Subjects
T cells -- Health aspects -- Methods, Cellular therapy -- Methods -- Health aspects, Nervous system tumors -- Care and treatment, Antigens -- Health aspects -- Methods, Tumors in children -- Care and treatment, Biological sciences, Health
Abstract

Atypical teratoid/rhabdoid tumors (ATRTs) typically arise in the central nervous system (CNS) of children under 3 years of age. Despite intensive multimodal therapy (surgery, chemotherapy and, if age permits, radiotherapy), median survival is 17 months.sup.1,2. We show that ATRTs robustly express B7-H3/CD276 that does not result from the inactivating mutations in SMARCB1 (refs. .sup.3,4), which drive oncogenesis in ATRT, but requires residual SWItch/Sucrose Non-Fermentable (SWI/SNF) activity mediated by BRG1/SMARCA4. Consistent with the embryonic origin of ATRT.sup.5,6, B7-H3 is highly expressed on the prenatal, but not postnatal, brain. B7-H3.BB.z-chimeric antigen receptor (CAR) T cells administered intracerebroventricularly or intratumorally mediate potent antitumor effects against cerebral ATRT xenografts in mice, with faster kinetics, greater potency and reduced systemic levels of inflammatory cytokines compared to CAR T cells administered intravenously. CAR T cells administered ICV also traffic from the CNS into the periphery; following clearance of ATRT xenografts, B7-H3.BB.z-CAR T cells administered intracerebroventricularly or intravenously mediate antigen-specific protection from tumor rechallenge, both in the brain and periphery. These results identify B7-H3 as a compelling therapeutic target for this largely incurable pediatric tumor and demonstrate important advantages of locoregional compared to systemic delivery of CAR T cells for the treatment of CNS malignancies. CAR T cells administered intracerebroventricularly or intratumorally exhibit more rapid kinetics, reduced systemic toxicity and greater therapeutic potency as compared to intravenously delivered CAR T cells in atypical teratoid/rhabdoid tumor xenograft mouse models., Author(s): Johanna Theruvath [sup.1] , Elena Sotillo [sup.1] , Christopher W. Mount [sup.2] , Claus Moritz Graef [sup.1] , Alberto Delaidelli [sup.3] , Sabine Heitzeneder [sup.1] , Louai Labanieh [sup.1] [...]

Published
2020
Full Text
View/download PDF

7. BET Bromodomain Inhibition of MYC-Amplified Medulloblastoma

Author

Bandopadhayay, Pratiti, Bergthold, Guillaume, Nguyen, Brian, Schubert, Simone, Gholamin, Sharareh, Tang, Yujie, Bolin, Sara, Schumacher, Steven E, Zeid, Rhamy, Masoud, Sabran, Yu, Furong, Vue, Nujsaubnusi, Gibson, William J, Paolella, Brenton R, Mitra, Siddhartha S, Cheshier, Samuel H, Qi, Jun, Liu, Kun-Wei, Wechsler-Reya, Robert, Weiss, William A, Swartling, Fredrik J, Kieran, Mark W, Bradner, James E, Beroukhim, Rameen, and Cho, Yoon-Jae

Subjects
Biotechnology, Neurosciences, Brain Disorders, Pediatric Cancer, Rare Diseases, Genetics, Cancer, Pediatric, Brain Cancer, Pediatric Research Initiative, Development of treatments and therapeutic interventions, 5.1 Pharmaceuticals, Animals, Antineoplastic Agents, Azepines, Cell Cycle Proteins, Cell Line, Tumor, Cell Survival, G1 Phase Cell Cycle Checkpoints, Gene Amplification, Gene Dosage, Humans, Medulloblastoma, Mice, Mice, Inbred NOD, Mice, SCID, Nuclear Proteins, Proto-Oncogene Proteins c-myc, Signal Transduction, Transcription Factors, Triazoles, Xenograft Model Antitumor Assays, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeMYC-amplified medulloblastomas are highly lethal tumors. Bromodomain and extraterminal (BET) bromodomain inhibition has recently been shown to suppress MYC-associated transcriptional activity in other cancers. The compound JQ1 inhibits BET bromodomain-containing proteins, including BRD4. Here, we investigate BET bromodomain targeting for the treatment of MYC-amplified medulloblastoma.Experimental designWe evaluated the effects of genetic and pharmacologic inhibition of BET bromodomains on proliferation, cell cycle, and apoptosis in established and newly generated patient- and genetically engineered mouse model (GEMM)-derived medulloblastoma cell lines and xenografts that harbored amplifications of MYC or MYCN. We also assessed the effect of JQ1 on MYC expression and global MYC-associated transcriptional activity. We assessed the in vivo efficacy of JQ1 in orthotopic xenografts established in immunocompromised mice.ResultsTreatment of MYC-amplified medulloblastoma cells with JQ1 decreased cell viability associated with arrest at G1 and apoptosis. We observed downregulation of MYC expression and confirmed the inhibition of MYC-associated transcriptional targets. The exogenous expression of MYC from a retroviral promoter reduced the effect of JQ1 on cell viability, suggesting that attenuated levels of MYC contribute to the functional effects of JQ1. JQ1 significantly prolonged the survival of orthotopic xenograft models of MYC-amplified medulloblastoma (P < 0.001). Xenografts harvested from mice after five doses of JQ1 had reduced the expression of MYC mRNA and a reduced proliferative index.ConclusionJQ1 suppresses MYC expression and MYC-associated transcriptional activity in medulloblastomas, resulting in an overall decrease in medulloblastoma cell viability. These preclinical findings highlight the promise of BET bromodomain inhibitors as novel agents for MYC-amplified medulloblastoma.

Published
2014

8. Usp16 contributes to somatic stem-cell defects in Down’s syndrome

Author

Adorno, Maddalena, Sikandar, Shaheen, Mitra, Siddhartha S, Kuo, Angera, Nicolis di Robilant, Benedetta, Haro-Acosta, Veronica, Ouadah, Youcef, Quarta, Marco, Rodriguez, Jacqueline, Qian, Dalong, Reddy, Vadiyala M, Cheshier, Samuel, Garner, Craig C, and Clarke, Michael F

Subjects
Biochemistry and Cell Biology, Biomedical and Clinical Sciences, Biological Sciences, Genetics, Stem Cell Research, Intellectual and Developmental Disabilities (IDD), Down Syndrome, Stem Cell Research - Nonembryonic - Non-Human, Brain Disorders, 1.1 Normal biological development and functioning, Aetiology, Underpinning research, 2.1 Biological and endogenous factors, Adult Stem Cells, Animals, Cell Proliferation, Cellular Senescence, Chromosomes, Human, Pair 21, Cyclin-Dependent Kinase Inhibitor p16, Disease Models, Animal, Epithelium, Female, Fibroblasts, Gene Dosage, Gene Expression Regulation, Hematopoietic Stem Cells, Humans, Mammary Glands, Animal, Mice, Molecular Targeted Therapy, Neural Stem Cells, Trisomy, Ubiquitin Thiolesterase, Ubiquitination, General Science & Technology
Abstract

Down's syndrome results from full or partial trisomy of chromosome 21. However, the consequences of the underlying gene-dosage imbalance on adult tissues remain poorly understood. Here we show that in Ts65Dn mice, which are trisomic for 132 genes homologous to genes on human chromosome 21, triplication of Usp16 reduces the self-renewal of haematopoietic stem cells and the expansion of mammary epithelial cells, neural progenitors and fibroblasts. In addition, Usp16 is associated with decreased ubiquitination of Cdkn2a and accelerated senescence in Ts65Dn fibroblasts. Usp16 can remove ubiquitin from histone H2A on lysine 119, a critical mark for the maintenance of multiple somatic tissues. Downregulation of Usp16, either by mutation of a single normal Usp16 allele or by short interfering RNAs, largely rescues all of these defects. Furthermore, in human tissues overexpression of USP16 reduces the expansion of normal fibroblasts and postnatal neural progenitors, whereas downregulation of USP16 partially rescues the proliferation defects of Down's syndrome fibroblasts. Taken together, these results suggest that USP16 has an important role in antagonizing the self-renewal and/or senescence pathways in Down's syndrome and could serve as an attractive target to ameliorate some of the associated pathologies.

Published
2013

9. Supplementary Table 3 from BET Bromodomain Inhibition of MYC-Amplified Medulloblastoma

Author

Bandopadhayay, Pratiti, primary, Bergthold, Guillaume, primary, Nguyen, Brian, primary, Schubert, Simone, primary, Gholamin, Sharareh, primary, Tang, Yujie, primary, Bolin, Sara, primary, Schumacher, Steven E., primary, Zeid, Rhamy, primary, Masoud, Sabran, primary, Yu, Furong, primary, Vue, Nujsaubnusi, primary, Gibson, William J., primary, Paolella, Brenton R., primary, Mitra, Siddhartha S., primary, Cheshier, Samuel H., primary, Qi, Jun, primary, Liu, Kun-Wei, primary, Wechsler-Reya, Robert, primary, Weiss, William A., primary, Swartling, Fredrik J., primary, Kieran, Mark W., primary, Bradner, James E., primary, Beroukhim, Rameen, primary, and Cho, Yoon-Jae, primary

Published
2023
Full Text
View/download PDF

10. Supplementary Table 2 from BET Bromodomain Inhibition of MYC-Amplified Medulloblastoma

Author

Bandopadhayay, Pratiti, primary, Bergthold, Guillaume, primary, Nguyen, Brian, primary, Schubert, Simone, primary, Gholamin, Sharareh, primary, Tang, Yujie, primary, Bolin, Sara, primary, Schumacher, Steven E., primary, Zeid, Rhamy, primary, Masoud, Sabran, primary, Yu, Furong, primary, Vue, Nujsaubnusi, primary, Gibson, William J., primary, Paolella, Brenton R., primary, Mitra, Siddhartha S., primary, Cheshier, Samuel H., primary, Qi, Jun, primary, Liu, Kun-Wei, primary, Wechsler-Reya, Robert, primary, Weiss, William A., primary, Swartling, Fredrik J., primary, Kieran, Mark W., primary, Bradner, James E., primary, Beroukhim, Rameen, primary, and Cho, Yoon-Jae, primary

Published
2023
Full Text
View/download PDF

11. Supplemental Figure 3b from Phase Ib Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia

Author

Danilov, Alexey V., primary, Herbaux, Charles, primary, Walter, Harriet S., primary, Hillmen, Peter, primary, Rule, Simon A., primary, Kio, Ebenezer A., primary, Karlin, Lionel, primary, Dyer, Martin J.S., primary, Mitra, Siddhartha S., primary, Yi, Ping Cheng, primary, Humeniuk, Rita, primary, Huang, Xi, primary, Zhou, Ziqian, primary, Bhargava, Pankaj, primary, Jürgensmeier, Juliane M., primary, and Fegan, Christopher D., primary

Published
2023
Full Text
View/download PDF

12. Supplemental Figure 2 from Phase Ib Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia

Author

Danilov, Alexey V., primary, Herbaux, Charles, primary, Walter, Harriet S., primary, Hillmen, Peter, primary, Rule, Simon A., primary, Kio, Ebenezer A., primary, Karlin, Lionel, primary, Dyer, Martin J.S., primary, Mitra, Siddhartha S., primary, Yi, Ping Cheng, primary, Humeniuk, Rita, primary, Huang, Xi, primary, Zhou, Ziqian, primary, Bhargava, Pankaj, primary, Jürgensmeier, Juliane M., primary, and Fegan, Christopher D., primary

Published
2023
Full Text
View/download PDF

13. Supplementary Data from CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors

Author

Majzner, Robbie G., primary, Theruvath, Johanna L., primary, Nellan, Anandani, primary, Heitzeneder, Sabine, primary, Cui, Yongzhi, primary, Mount, Christopher W., primary, Rietberg, Skyler P., primary, Linde, Miles H., primary, Xu, Peng, primary, Rota, Christopher, primary, Sotillo, Elena, primary, Labanieh, Louai, primary, Lee, Daniel W., primary, Orentas, Rimas J., primary, Dimitrov, Dimiter S., primary, Zhu, Zhongyu, primary, Croix, Brad St, primary, Delaidelli, Alberto, primary, Sekunova, Alla, primary, Bonvini, Ezio, primary, Mitra, Siddhartha S., primary, Quezado, Martha M., primary, Majeti, Ravindra, primary, Monje, Michelle, primary, Sorensen, Poul H.B., primary, Maris, John M., primary, and Mackall, Crystal L., primary

Published
2023
Full Text
View/download PDF

14. Supplemental Figure 1 from Phase Ib Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia

Author

Danilov, Alexey V., primary, Herbaux, Charles, primary, Walter, Harriet S., primary, Hillmen, Peter, primary, Rule, Simon A., primary, Kio, Ebenezer A., primary, Karlin, Lionel, primary, Dyer, Martin J.S., primary, Mitra, Siddhartha S., primary, Yi, Ping Cheng, primary, Humeniuk, Rita, primary, Huang, Xi, primary, Zhou, Ziqian, primary, Bhargava, Pankaj, primary, Jürgensmeier, Juliane M., primary, and Fegan, Christopher D., primary

Published
2023
Full Text
View/download PDF

15. Supplementary Table 1 from BET Bromodomain Inhibition of MYC-Amplified Medulloblastoma

Author

Bandopadhayay, Pratiti, primary, Bergthold, Guillaume, primary, Nguyen, Brian, primary, Schubert, Simone, primary, Gholamin, Sharareh, primary, Tang, Yujie, primary, Bolin, Sara, primary, Schumacher, Steven E., primary, Zeid, Rhamy, primary, Masoud, Sabran, primary, Yu, Furong, primary, Vue, Nujsaubnusi, primary, Gibson, William J., primary, Paolella, Brenton R., primary, Mitra, Siddhartha S., primary, Cheshier, Samuel H., primary, Qi, Jun, primary, Liu, Kun-Wei, primary, Wechsler-Reya, Robert, primary, Weiss, William A., primary, Swartling, Fredrik J., primary, Kieran, Mark W., primary, Bradner, James E., primary, Beroukhim, Rameen, primary, and Cho, Yoon-Jae, primary

Published
2023
Full Text
View/download PDF

16. Supplementary Figure 2 from BET Bromodomain Inhibition of MYC-Amplified Medulloblastoma

Author

Bandopadhayay, Pratiti, primary, Bergthold, Guillaume, primary, Nguyen, Brian, primary, Schubert, Simone, primary, Gholamin, Sharareh, primary, Tang, Yujie, primary, Bolin, Sara, primary, Schumacher, Steven E., primary, Zeid, Rhamy, primary, Masoud, Sabran, primary, Yu, Furong, primary, Vue, Nujsaubnusi, primary, Gibson, William J., primary, Paolella, Brenton R., primary, Mitra, Siddhartha S., primary, Cheshier, Samuel H., primary, Qi, Jun, primary, Liu, Kun-Wei, primary, Wechsler-Reya, Robert, primary, Weiss, William A., primary, Swartling, Fredrik J., primary, Kieran, Mark W., primary, Bradner, James E., primary, Beroukhim, Rameen, primary, and Cho, Yoon-Jae, primary

Published
2023
Full Text
View/download PDF

17. Supplementary Figure 1 from BET Bromodomain Inhibition of MYC-Amplified Medulloblastoma

Author

Bandopadhayay, Pratiti, primary, Bergthold, Guillaume, primary, Nguyen, Brian, primary, Schubert, Simone, primary, Gholamin, Sharareh, primary, Tang, Yujie, primary, Bolin, Sara, primary, Schumacher, Steven E., primary, Zeid, Rhamy, primary, Masoud, Sabran, primary, Yu, Furong, primary, Vue, Nujsaubnusi, primary, Gibson, William J., primary, Paolella, Brenton R., primary, Mitra, Siddhartha S., primary, Cheshier, Samuel H., primary, Qi, Jun, primary, Liu, Kun-Wei, primary, Wechsler-Reya, Robert, primary, Weiss, William A., primary, Swartling, Fredrik J., primary, Kieran, Mark W., primary, Bradner, James E., primary, Beroukhim, Rameen, primary, and Cho, Yoon-Jae, primary

Published
2023
Full Text
View/download PDF

18. Supplementary Figure 3 from BET Bromodomain Inhibition of MYC-Amplified Medulloblastoma

Author

Bandopadhayay, Pratiti, primary, Bergthold, Guillaume, primary, Nguyen, Brian, primary, Schubert, Simone, primary, Gholamin, Sharareh, primary, Tang, Yujie, primary, Bolin, Sara, primary, Schumacher, Steven E., primary, Zeid, Rhamy, primary, Masoud, Sabran, primary, Yu, Furong, primary, Vue, Nujsaubnusi, primary, Gibson, William J., primary, Paolella, Brenton R., primary, Mitra, Siddhartha S., primary, Cheshier, Samuel H., primary, Qi, Jun, primary, Liu, Kun-Wei, primary, Wechsler-Reya, Robert, primary, Weiss, William A., primary, Swartling, Fredrik J., primary, Kieran, Mark W., primary, Bradner, James E., primary, Beroukhim, Rameen, primary, and Cho, Yoon-Jae, primary

Published
2023
Full Text
View/download PDF

19. Supplementary Data from Phase Ib Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia

Author

Danilov, Alexey V., primary, Herbaux, Charles, primary, Walter, Harriet S., primary, Hillmen, Peter, primary, Rule, Simon A., primary, Kio, Ebenezer A., primary, Karlin, Lionel, primary, Dyer, Martin J.S., primary, Mitra, Siddhartha S., primary, Yi, Ping Cheng, primary, Humeniuk, Rita, primary, Huang, Xi, primary, Zhou, Ziqian, primary, Bhargava, Pankaj, primary, Jürgensmeier, Juliane M., primary, and Fegan, Christopher D., primary

Published
2023
Full Text
View/download PDF

20. Supplemental Figure 4 from Phase Ib Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia

Author

Danilov, Alexey V., primary, Herbaux, Charles, primary, Walter, Harriet S., primary, Hillmen, Peter, primary, Rule, Simon A., primary, Kio, Ebenezer A., primary, Karlin, Lionel, primary, Dyer, Martin J.S., primary, Mitra, Siddhartha S., primary, Yi, Ping Cheng, primary, Humeniuk, Rita, primary, Huang, Xi, primary, Zhou, Ziqian, primary, Bhargava, Pankaj, primary, Jürgensmeier, Juliane M., primary, and Fegan, Christopher D., primary

Published
2023
Full Text
View/download PDF

21. Supplementary Table 4 from BET Bromodomain Inhibition of MYC-Amplified Medulloblastoma

Author

Bandopadhayay, Pratiti, primary, Bergthold, Guillaume, primary, Nguyen, Brian, primary, Schubert, Simone, primary, Gholamin, Sharareh, primary, Tang, Yujie, primary, Bolin, Sara, primary, Schumacher, Steven E., primary, Zeid, Rhamy, primary, Masoud, Sabran, primary, Yu, Furong, primary, Vue, Nujsaubnusi, primary, Gibson, William J., primary, Paolella, Brenton R., primary, Mitra, Siddhartha S., primary, Cheshier, Samuel H., primary, Qi, Jun, primary, Liu, Kun-Wei, primary, Wechsler-Reya, Robert, primary, Weiss, William A., primary, Swartling, Fredrik J., primary, Kieran, Mark W., primary, Bradner, James E., primary, Beroukhim, Rameen, primary, and Cho, Yoon-Jae, primary

Published
2023
Full Text
View/download PDF

22. Supplementary Table 5 from BET Bromodomain Inhibition of MYC-Amplified Medulloblastoma

Author

Bandopadhayay, Pratiti, primary, Bergthold, Guillaume, primary, Nguyen, Brian, primary, Schubert, Simone, primary, Gholamin, Sharareh, primary, Tang, Yujie, primary, Bolin, Sara, primary, Schumacher, Steven E., primary, Zeid, Rhamy, primary, Masoud, Sabran, primary, Yu, Furong, primary, Vue, Nujsaubnusi, primary, Gibson, William J., primary, Paolella, Brenton R., primary, Mitra, Siddhartha S., primary, Cheshier, Samuel H., primary, Qi, Jun, primary, Liu, Kun-Wei, primary, Wechsler-Reya, Robert, primary, Weiss, William A., primary, Swartling, Fredrik J., primary, Kieran, Mark W., primary, Bradner, James E., primary, Beroukhim, Rameen, primary, and Cho, Yoon-Jae, primary

Published
2023
Full Text
View/download PDF

23. Supplementary Table 1 - 3 from Targeting a Glioblastoma Cancer Stem-Cell Population Defined by EGF Receptor Variant III

Author

Emlet, David R., primary, Gupta, Puja, primary, Holgado-Madruga, Marina, primary, Del Vecchio, Catherine A., primary, Mitra, Siddhartha S., primary, Han, Shuang-Yin, primary, Li, Gordon, primary, Jensen, Kristin C., primary, Vogel, Hannes, primary, Xu, Linda Wei, primary, Skirboll, Stephen S., primary, and Wong, Albert J., primary

Published
2023
Full Text
View/download PDF

25. Supplementary Figures 1 - 5 from Targeting a Glioblastoma Cancer Stem-Cell Population Defined by EGF Receptor Variant III

Author

Emlet, David R., primary, Gupta, Puja, primary, Holgado-Madruga, Marina, primary, Del Vecchio, Catherine A., primary, Mitra, Siddhartha S., primary, Han, Shuang-Yin, primary, Li, Gordon, primary, Jensen, Kristin C., primary, Vogel, Hannes, primary, Xu, Linda Wei, primary, Skirboll, Stephen S., primary, and Wong, Albert J., primary

Published
2023
Full Text
View/download PDF

27. Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors

Author

Gholamin, Sharareh, Mitra, Siddhartha S., Feroze, Abdullah H., Liu, Jie, Kahn, Suzana A., Zhang, Michael, Esparza, Rogelio, Richard, Chase, Ramaswamy, Vijay, Remke, Marc, Volkmer, Anne K., Willingham, Stephen, Ponnuswami, Anitha, McCarty, Aaron, Lovelace, Patricia, Storm, Theresa A., Schubert, Simone, Hutter, Gregor, Narayanan, Cyndhavi, Chu, Pauline, Raabe, Eric H., Harsh, Griffith, IV, Taylor, Michael D., Monje, Michelle, Cho, Yoon-Jae, Majeti, Ravi, Volkmer, Jens P., Fisher, Paul G., Grant, Gerald, Steinberg, Gary K., Vogel, Hannes, Edwards, Michael, Weissman, Irving L., and Cheshier, Samuel H.

Published
2017
Full Text
View/download PDF

28. Notch1 regulates the initiation of metastasis and self-renewal of Group 3 medulloblastoma

Author

Kahn, Suzana A., Wang, Xin, Nitta, Ryan T., Gholamin, Sharareh, Theruvath, Johanna, Hutter, Gregor, Azad, Tej D., Wadi, Lina, Bolin, Sara, Ramaswamy, Vijay, Esparza, Rogelio, Liu, Kun-Wei, Edwards, Michael, Swartling, Fredrik J., Sahoo, Debashis, Li, Gordon, Wechsler-Reya, Robert J., Reimand, Jüri, Cho, Yoon-Jae, Taylor, Michael D., Weissman, Irving L., Mitra, Siddhartha S., and Cheshier, Samuel H.

Published
2018
Full Text
View/download PDF

30. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors

Author

Willingham, Stephen B., Volkmer, Jens-Peter, Gentles, Andrew J., Sahoo, Debashis, Dalerba, Piero, Mitra, Siddhartha S., Wang, Jian, Contreras-Trujillo, Humberto, Martin, Robin, Cohen, Justin D., Lovelace, Patricia, Scheeren, Ferenc A., Chao, Mark P., Weiskopf, Kipp, Tang, Chad, Volkmer, Anne Kathrin, Naik, Tejaswitha J., Storm, Theresa A., Mosley, Adriane R., Edris, Badreddin, Schmid, Seraina M., Sun, Chris K., Chua, Mei-Sze, Murillo, Oihana, Rajendran, Pradeep, Cha, Adriel C., Chin, Robert K., Kim, Dongkyoon, Adorno, Maddalena, Raveh, Tal, Tseng, Diane, Jaiswal, Siddhartha, Enger, Per Øyvind, Steinberg, Gary K., Li, Gordon, So, Samuel K., Majeti, Ravindra, Harsh, Griffith R., van de Rijn, Matt, Teng, Nelson N. H., Sunwoo, John B., Alizadeh, Ash A., Clarke, Michael F., and Weissman, Irving L.

Published
2012

31. Venetoclax Cooperates with Ionizing Radiation to Attenuate Diffuse Midline Glioma Tumor Growth

Author

Madhavan, Krishna, primary, Balakrishnan, Ilango, additional, Lakshmanachetty, Senthilnath, additional, Pierce, Angela, additional, Sanford, Bridget, additional, Fosmire, Susan, additional, Elajaili, Hanan B., additional, Walker, Faye, additional, Wang, Dong, additional, Nozik, Eva S., additional, Mitra, Siddhartha S., additional, Dahl, Nathan A., additional, Vibhakar, Rajeev, additional, and Venkataraman, Sujatha, additional

Published
2022
Full Text
View/download PDF

32. List of Contributors

Author

Agro, Lauren, primary, Bao, Shideng, additional, Chang, Chi-Hsuan, additional, Chan, Keith Syson, additional, Cheshier, Samuel H., additional, Chopra, Avijeet S., additional, Chumakova, Anastasia, additional, Clarke, Michael F., additional, Condello, Salvatore, additional, Donahue, Leanne R., additional, Esparza, Rogelio, additional, Fang, Fang, additional, Fillmore Brainson, Christine, additional, Gurney, Austin, additional, Haller, Andrew, additional, Haynes, Jennifer, additional, Heiser, Diane, additional, He, Joy Q., additional, Hitomi, Masahiro, additional, Hoey, Timothy, additional, Hseih, Jason K., additional, Hutter, Gregor, additional, Jarrar, Awad, additional, Kim, Carla F., additional, Kozminsky, Molly, additional, Kurtova, Antonina V., additional, Lathia, Justin D., additional, Leung, Cherry, additional, Lima-Fernandes, Evelyne, additional, Liu, Huiping, additional, Liu, Xia, additional, Lobo, Neethan A., additional, Matei, Daniela, additional, Mitra, Siddhartha S., additional, Moon, Hyeongsun, additional, Nagrath, Sunitha, additional, Nephew, Kenneth P., additional, O’Brien, Catherine A., additional, Petritsch, Claudia, additional, Puri, Akshita, additional, Qian, Dalong, additional, Rehman, Sumaiyah, additional, Reizes, Ofer, additional, Rosen, Jeffrey M., additional, Rycaj, Kiera, additional, Saunthararajah, Yogen, additional, Shen, Xiling, additional, Sloan, Andrew E., additional, Spike, Benjamin T., additional, Sundar, Swetha J., additional, Tang, Dean G., additional, Thiagarajan, Praveena S., additional, van Weele, Linda J., additional, Wang, Yadong, additional, Wang, Yinu, additional, Weissman, Irving, additional, White, Andrew C., additional, Wright, James, additional, Zabala, Maider, additional, and Zhou, Wenchao, additional

Published
2016
Full Text
View/download PDF

34. The anti-hypertensive drug prazosin inhibits glioblastoma growth via the PKCδ-dependent inhibition of the AKT pathway

Author

Kahn, Suzana Assad, Costa, Silvia Lima, Gholamin, Sharareh, Nitta, Ryan T, Dubois, Luiz Gustavo, Fève, Marie, Zeniou, Maria, Coelho, Paulo Lucas Cerqueira, El-Habr, Elias, Cadusseau, Josette, Varlet, Pascale, Mitra, Siddhartha S, Devaux, Bertrand, Kilhoffer, Marie-Claude, Cheshier, Samuel H, Moura-Neto, Vivaldo, Haiech, Jacques, Junier, Marie-Pierre, and Chneiweiss, Hervé

Published
2016
Full Text
View/download PDF

39. Phase Ib Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia

Author

Danilov, Alexey V., primary, Herbaux, Charles, additional, Walter, Harriet S., additional, Hillmen, Peter, additional, Rule, Simon A., additional, Kio, Ebenezer A., additional, Karlin, Lionel, additional, Dyer, Martin J.S., additional, Mitra, Siddhartha S., additional, Yi, Ping Cheng, additional, Humeniuk, Rita, additional, Huang, Xi, additional, Zhou, Ziqian, additional, Bhargava, Pankaj, additional, Jürgensmeier, Juliane M., additional, and Fegan, Christopher D., additional

Published
2020
Full Text
View/download PDF

40. CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors

Author

Majzner, Robbie G., primary, Theruvath, Johanna L., additional, Nellan, Anandani, additional, Heitzeneder, Sabine, additional, Cui, Yongzhi, additional, Mount, Christopher W., additional, Rietberg, Skyler P., additional, Linde, Miles H., additional, Xu, Peng, additional, Rota, Christopher, additional, Sotillo, Elena, additional, Labanieh, Louai, additional, Lee, Daniel W., additional, Orentas, Rimas J., additional, Dimitrov, Dimiter S., additional, Zhu, Zhongyu, additional, Croix, Brad St, additional, Delaidelli, Alberto, additional, Sekunova, Alla, additional, Bonvini, Ezio, additional, Mitra, Siddhartha S., additional, Quezado, Martha M., additional, Majeti, Ravindra, additional, Monje, Michelle, additional, Sorensen, Poul H.B., additional, Maris, John M., additional, and Mackall, Crystal L., additional

Published
2019
Full Text
View/download PDF

41. Development of an EGFRvIII specific recombinant antibody

Author

Li Gordon, Mitra Siddhartha S, Holgado-Madruga Marina, Han Shuang-Yin, Gupta Puja, Nitta Ryan T, and Wong Albert J

Subjects
Biotechnology, TP248.13-248.65
Abstract

Abstract Background EGF receptor variant III (EGFRvIII) is the most common variant of the EGF receptor observed in human tumors. It results from the in frame deletion of exons 2-7 and the generation of a novel glycine residue at the junction of exons 1 and 8. This novel juxtaposition of amino acids within the extra-cellular domain of the EGF receptor creates a tumor specific and immunogenic epitope. EGFRvIII expression has been seen in many tumor types including glioblastoma multiforme (GBM), breast adenocarcinoma, non-small cell lung carcinoma, ovarian adenocarcinoma and prostate cancer, but has been rarely observed in normal tissue. Because this variant is tumor specific and highly immunogenic, it can be used for both a diagnostic marker as well as a target for immunotherapy. Unfortunately many of the monoclonal and polyclonal antibodies directed against EGFRvIII have cross reactivity to wild type EGFR or other non-specific proteins. Furthermore, a monoclonal antibody to EGFRvIII is not readily available to the scientific community. Results In this study, we have developed a recombinant antibody that is specific for EGFRvIII, has little cross reactivity for the wild type receptor, and which can be easily produced. We initially designed a recombinant antibody with two anti-EGFRvIII single chain Fv's linked together and a human IgG1 Fc component. To enhance the specificity of this antibody for EGFRvIII, we mutated tyrosine H59 of the CDRH2 domain and tyrosine H105 of the CDRH3 domain to phenylalanine for both the anti-EGFRvIII sequence inserts. This mutated recombinant antibody, called RAbDMvIII, specifically detects EGFRvIII expression in EGFRvIII expressing cell lines as well as in EGFRvIII expressing GBM primary tissue by western blot, immunohistochemistry (IHC) and immunofluorescence (IF) and FACS analysis. It does not recognize wild type EGFR in any of these assays. The affinity of this antibody for EGFRvIII peptide is 1.7 × 107 M-1 as determined by enzyme-linked immunosorbent assay (ELISA). Conclusion This recombinant antibody thus holds great potential to be used as a research reagent and diagnostic tool in research laboratories and clinics because of its high quality, easy viability and unique versatility. This antibody is also a strong candidate to be investigated for further in vivo therapeutic studies.

Published
2010
Full Text
View/download PDF

46. Surgical debulking promotes recruitment of macrophages and triggers glioblastoma phagocytosis in combination with CD47 blocking immunotherapy

Author

Zhu, Huaiyang, primary, Leiss, Lina, additional, Yang, Ning, additional, Rygh, Cecilie B., additional, Mitra, Siddhartha S., additional, Cheshier, Samuel H., additional, Weissman, Irving L., additional, Huang, Bin, additional, Miletic, Hrvoje, additional, Bjerkvig, Rolf, additional, Enger, Per Ø., additional, Li, Xingang, additional, and Wang, Jian, additional

Published
2017
Full Text
View/download PDF

47. Anti-CD47 Treatment Stimulates Phagocytosis of Glioblastoma by M1 and M2 Polarized Macrophages and Promotes M1 Polarized Macrophages In Vivo

Author

Zhang, Michael, primary, Hutter, Gregor, additional, Kahn, Suzana A., additional, Azad, Tej D., additional, Gholamin, Sharareh, additional, Xu, Chelsea Y., additional, Liu, Jie, additional, Achrol, Achal S., additional, Richard, Chase, additional, Sommerkamp, Pia, additional, Schoen, Matthew Kenneth, additional, McCracken, Melissa N., additional, Majeti, Ravi, additional, Weissman, Irving, additional, Mitra, Siddhartha S., additional, and Cheshier, Samuel H., additional

Published
2016
Full Text
View/download PDF

48. The anti‐hypertensive drug prazosin inhibits glioblastoma growth via the PKC δ‐dependent inhibition of the AKT pathway

Author

Assad Kahn, Suzana, primary, Costa, Silvia Lima, additional, Gholamin, Sharareh, additional, Nitta, Ryan T, additional, Dubois, Luiz Gustavo, additional, Fève, Marie, additional, Zeniou, Maria, additional, Coelho, Paulo Lucas Cerqueira, additional, El‐Habr, Elias, additional, Cadusseau, Josette, additional, Varlet, Pascale, additional, Mitra, Siddhartha S, additional, Devaux, Bertrand, additional, Kilhoffer, Marie‐Claude, additional, Cheshier, Samuel H, additional, Moura‐Neto, Vivaldo, additional, Haiech, Jacques, additional, Junier, Marie‐Pierre, additional, and Chneiweiss, Hervé, additional

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results